(NASDAQ: TNGX) Tango Therapeutics's forecast annual revenue growth rate of -6.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.61%.
Tango Therapeutics's revenue in 2024 is $42,509,000.On average, 6 Wall Street analysts forecast TNGX's revenue for 2024 to be $4,546,461,083, with the lowest TNGX revenue forecast at $3,975,059,652, and the highest TNGX revenue forecast at $5,817,944,450. On average, 6 Wall Street analysts forecast TNGX's revenue for 2025 to be $3,636,590,287, with the lowest TNGX revenue forecast at $2,678,611,625, and the highest TNGX revenue forecast at $6,182,235,631.
In 2026, TNGX is forecast to generate $4,080,061,227 in revenue, with the lowest revenue forecast at $2,536,109,487 and the highest revenue forecast at $7,050,105,797.